Conmed Corp income statement

In fiscal 2025, Conmed Corp reported revenue of $1.37bn, up 5.2% on the year before, operating income of $103m (a 7.5% margin) and net income of $47.1m, or $1.51 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Conmed Corp: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	695	714	725	767	763	740	719	764	796	860	955	862	1,011	1,045	1,245	1,307	1,375
Cost of revenue	357	348	350	361	350	336	337	355	365	391	430	402	443	474	568	574	624
Gross profit	337	365	375	406	412	404	382	408	431	469	525	460	568	571	676	733	750
Research and development	32	30	29	28	26	28	27	32	32	42	45	40	44	47	53	54	56
Selling, general and administrative	266	276	277	302	330	323	303	338	352	356	400	374	415	454	503	478	592
Operating income	28	57	8	65	57	53	51	38	47	71	79	46	110	70	121	200	103
Interest expense	7	7	7	6	6	6	6	15	18	21	43	44	35	29	40	37	31
Income before tax	18	46	−2	59	51	47	45	19	29	51	31	2	73	−71	81	163	71
Income tax	6	15	−3	19	15	14	15	5	−27	10	3	−8	11	10	16	31	24
Net income	12	30	1	40	36	32	30	15	55	41	29	10	63	−81	64	132	47
Diluted EPS	$0.42	$1.05	$0.03	$1.41	$1.28	$1.16	$1.09	$0.52	$1.97	$1.41	$0.97	$0.32	$1.94	−$2.68	$2.04	$4.25	$1.51
Diluted shares (average)	29m	29m	29m	29m	28m	28m	28m	28m	28m	29m	29m	29m	32m	30m	32m	31m	31m
EBITDA	47	74	27	84	75	73	70	58	67	90	98	64	126	86	137	217	120

US$ millions unless shown otherwise. Fiscal quarters.

Conmed Corp: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	317	346	321	342	338	373	343	336
Cost of revenue	138	148	144	154	172	155	146	146
Gross profit	179	198	178	188	166	218	197	189
Research and development	14	13	13	14	14	15	16	16
Selling, general and administrative	100	133	149	136	140	167	146	136
Operating income	66	52	16	38	12	37	36	37
Interest expense	9	9	8	8	8	7	8	11
Income before tax	56	44	8	30	4	29	31	26
Income tax	7	10	2	8	1	13	8	6
Net income	49	34	6	21	3	17	23	20
Diluted EPS	$1.57	$1.08	$0.19	$0.69	$0.09	$0.54	$0.77	$0.66
EBITDA	70	57	20	43	16	41	—	41

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CNMD vs HAE CNMD vs STVN CNMD vs PEN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Conmed Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Conmed Corp.